Re: Reference links HIV drugs on market and in development Merck announced July 14 that it is abandoning development of vicriviroc, the company’s CCR5-blocking HIV entry inhibitor candidate. http://www.aidsmeds.com/articles/hiv_vicriviroc_merck_1667_18742.shtml